

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cryptofor 140 000 IU/ml Veterinary

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance:

paromomycin activity (as paromomycin sulfate) 140 000 IU/ml

Excipients:

Sodium metabisulfite (E223) 4.0 mg

Methyl parahydroxybenzoate (E218) 1.0 mg

Propyl parahydroxybenzoate 0.1 mg

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Oral solution.

A clear yellow to amber solution.

4. CLINICAL PARTICULARS

4.1 Target species

Sheep (pre-ruminant lambs)

goats (pre-ruminant kids).

4.2 Indications for use, specifying the target species

Reduction of the severity and the duration of diarrhoea associated with *Cryptosporidium parvum* in individual animals confirmed to have cryptosporidial oocysts in their faeces.

Paromomycin reduces faecal oocyst shedding.

4.3 Contraindications

Do not use in animals with known hypersensitivity to paromomycin, other aminoglycosides or any of the excipients listed in section 6.1.

Do not use in cases with impaired function of the kidneys or liver.

Do not use in ruminating animals.

4.4 Special warnings for each target species

Lambs and goat kids should only receive the treatment upon confirmation of cryptosporidial oocysts in their faeces and as soon as possible after the onset of diarrhoea (see section 4.5i).

In field studies investigating the effect of the product on diarrhoea associated with cryptosporidiosis, the median duration of clinically relevant diarrhoea was 3 days for treated lambs compared to 6 days for untreated lambs and 4 days in treated kid goats compared to 7 days for the untreated goats, during the 7-day treatment period.

4.5 Special precautions for use

Special precautions for use in animals

Since the product is potentially ototoxic and nephrotoxic, it is recommended to assess kidney function, especially when considering administration of the product to newborn animals due to the known higher gastrointestinal absorption of paromomycin in neonates. This higher absorption could lead to an increased risk of oto- and nephrotoxicity. The use of the product in neonates should be based on a benefit/risk assessment by the responsible veterinarian.

The use of the product should be combined with good management practices e.g. good hygiene, proper ventilation, no overstocking and thorough cleansing and disinfection.

Aminoglycosides are considered as critically important in human medicine. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to paromomycin and may decrease the effectiveness of treatment with aminoglycosides due to the potential for cross-resistance.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

This product contains paromomycin, which can cause allergic reactions in some people.

People with known hypersensitivity (allergy) to paromomycin or any other aminoglycosides should avoid contact with the veterinary medicinal product.

Avoid contact with the skin and eyes.

In the event of accidental contact with the skin or eyes, rinse with plenty of water.

If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the physician this warning. Swelling of the face, lips and eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.

Personal protective equipment consisting of protective clothing and impervious gloves should be worn when handling the veterinary medicinal product. Do not eat, drink and smoke when handling the product.

Do not ingest. In case of accidental ingestion, seek medical advice immediately and show the label to the physician.

Wash hands after use.

4.6 Adverse reactions (frequency and seriousness)

Aminoglycoside antibiotics such as paromomycin can cause oto- and nephrotoxicity.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorization of the medical product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form

<https://sideeffects.health.gov.il/>

4.7 Use during pregnancy, lactation or lay

Not applicable.

4.8 Interaction with other medicinal products and other forms of interaction

General anaesthetics and muscle relaxing products increases the neuro-blocking effect of aminoglycosides. This may cause paralysis and apnoea.

Do not use concurrently with strong diuretics and potentially oto- or nephrotoxic Substances

4.9 Amounts to be administered and administration route

For oral use.

Dose rate: 35 000 IU of paromomycin /kg BW /day for 7 consecutive days, i.e. 0.25 ml of product / 1 kg BW/day for 7 consecutive days.

The consecutive treatment should be done at the same time each day.

To ensure correct dosing, the bodyweight should be determined as accurately as possible and the use of either a syringe or any appropriate device for oral administration is necessary.

Only a single course of treatment should be administered to an individual animal.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

At 5 times the dose and 3 times the duration, no adverse effects have been observed in lambs.

4.11 Withdrawal period(s)

Meat and offal: 24 days

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: other antiprotozoal agents.

ATCvet code: QA 07 AA 06.

5.1 Pharmacodynamic properties

Paromomycin has antiprotozoal activity, although its mechanism of action is unclear. In in vitro studies using HCT-8 and Caco-2 cell lines inhibitory activity against *C. parvum* was observed. Resistance of cryptosporidia to paromomycin has not been described to date. Nevertheless, the use of aminoglycosides is associated with the occurrence of bacterial resistance. Paromomycin may select for cross-resistance to other aminoglycosides.

5.2 Pharmacokinetic particulars

IV injection in lambs at a dose rate of 7 000 IU / kg showed that paromomycin is rapidly eliminated ($T_{1/2} = 4.58$ hours) and that the clearance (2.49 ml/min/kg) was relatively low showing probably limited liver metabolism.

The bioavailability of paromomycin when administered as a single oral dose of 50 mg paromomycin sulphate/kg bodyweight to lambs was 13%. With regard to the absorbed fraction, the mean peak plasma concentration (C_{max}) was 2.68 mg/l, the mean time to attain the peak plasma concentration (T_{max}) was 4 hours and the mean terminal half-life ($t_{1/2, el}$) was 27.4 hours. The main part of the dose is eliminated unchanged in the faeces.

5.3 Environmental properties

The active ingredient paromomycin is very persistent in the environment.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Purified water

Sodium metabisulfite (E223)

Methyl parahydroxybenzoate (E218)

Propyl parahydroxybenzoate

6.2 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

6.3 Shelf life

The expiry date of the product is indicated on the packaging materials.

Shelf life after first opening the immediate packaging: 3 months.

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and composition of immediate packaging

White high-density polyethylene bottles with tamper-evident polypropylene screw closures.

Pack sizes are

125 ml

250 ml

500 ml

1 L

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. Registration HOLDER

M.P Vet

POB 7004

Petach-Tiqva 49170

8. Registration NUMBER

174-04-36500-99

Approved in:

09/2023